價(jià)格 | ¥333 | ¥482 | ¥793 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2025-02-28 |
中文名稱:化合物 Ddr1-In-1 | 英文名稱:Ddr1-In-1 |
CAS:1449685-96-4 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.84% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T3337 |
名稱 | Ddr1-In-1 |
描述 | DDR1-IN-1 is an effective and specific DDR1 receptor tyrosine kinase inhibitor (IC50: 105 nM), about 3-fold selectivity over DDR2. |
細(xì)胞實(shí)驗(yàn) | Cells are plated in triplicate at a density of 3000 cells per well in 96-well plates and 1500 cells per well in 384-well plates. Compounds of various concentrations are added into plates for 48 hours. Cell viability is determined using the CellTiter-Glo and CCK-8. Both assays are performed according to the manufacturer's instructions. For CellTiter-Glo assay, luminescence is determined in a multi-label reader. For CCK-8 assay, absorbance is measured in a microplate reader at 450 nM. Data are normalized to control group (DMSO) and represented by the mean of at least two independent measurement with standard error <20%. GI50 were calculated using Prism 5.0.(Only for Reference) |
激酶實(shí)驗(yàn) | General procedure for the EC50 test: DDR1 is induced by 2 Gg/ml doxycycline for 48 hrs prior to DDR1 activation by rat tail collagen I. The DDR1 over-expressed U2OS is pre-treated by media containing each concentration of the compound for 1 hr and treated by changing the media to the EC50 test media containing 10 Gg/ml collagen and each concentration of the compound for 2 hrs. Each cells is washed with cold PBS three times and lysed with the lysis buffer (50 mMTris, pH 7.5, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 5 mM EDTA, 100 mMNaF, 2 mM Na3VO4, 1 mM PMSF, 10 Gg/ml aprotinin, and 10 Gg/ml leupeptin). The activation of DDR1 is quantified by density using program ImageJ to determine EC50 following Western blot using anti-activated human DDR1b (Y513). |
體外活性 | 在U2OS細(xì)胞中,DDR1-IN-1通過EC50為86 nM抑制DDR1的基礎(chǔ)自磷酸化,并且在沒有膠原蛋白刺激的情況下顯示出更強(qiáng)的DDR1自磷酸化抑制作用。在一系列具有DDR1功能增益突變和/或過表達(dá)的不同癌癥細(xì)胞株中,DDR1-IN-1在低于10 μM的濃度下不抑制增殖,而GSK2126458增強(qiáng)了DDR1-IN-1的抗增殖活性。[1] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 93 mg/mL (168.3 mM) Ethanol : 4 mg/mL (7.23 mM), Heating is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) |
關(guān)鍵字 | Discoidin Domain Receptor | inhibit | Ddr-1-In-1 | Inhibitor | Ddr1 In 1 | Ddr1In1 | Ddr1-In-1 |
相關(guān)產(chǎn)品 | DDR Inhibitor | FGFR1/DDR2 inhibitor 1 | DDR1-IN-2 | WRG-28 | Merestinib | Sitravatinib | VU6015929 | (S)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-2-(pyrimidin-5-yl)-1,2,3,4-tetrahydroisoquinoline-7-carboxamide | DDR-TRK-1 | LCB 03-0110 | DDR1-IN-4 |
相關(guān)庫(kù) | 抑制劑庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) | 激酶抑制劑庫(kù) | 含氟化合物庫(kù) | NO PAINS 化合物庫(kù) | 抗COVID-19化合物庫(kù) | 膜蛋白靶向化合物庫(kù) | 酪氨酸激酶分子庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP5年
|
蘇州優(yōu)睿科化工醫(yī)藥科技有限公司
|
2025-03-30 | |
詢價(jià) |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-03-14 | |
詢價(jià) |
VIP3年
|
湖北威德利化學(xué)試劑有限公司
|
2025-04-03 | |
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2025-04-03 | |
¥846.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2025-02-27 |